Skyhawk Therapeutics Enters a ~$2B Deal with Merck KGaA to Identify RNA-Targeting Small Molecules for Neurological Disorders

Shots: Skyhawk Therapeutics has entered into a strategic research collaboration with Merck KGaA to discover novel RNA-targeting small molecules for neurological diseases with limited treatment options Skyhawk will receive ~$2B incl. upfront, milestones, & potential tiered royalties, leading discovery & preclinical development, while Merck KGaA gains exclusive global rights & handles further development & commercialization upon…

ByRidhi Rastogi4 days ago

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the US FDA’s clearance of Neural Sleeve for patients with cerebral palsy, MS, stroke, and other disorders Cionic’s Neural Sleeve has received the US FDA clearance for functional electrical stimulation to assist in gait for patients with foot drop and leg muscle weakness. The lightweight…

BySenior EditorMarch 30, 2022

8th International Conference on Neurology and Neuroscience 2020

After 7 series of successful conferences, we are back afresh with the 8th International Conference on Neurology and Neuroscience, curated by a panel of expert neuroscientists and neurologists on the dates April 06-07, 2020 in Dubai, UAE. With an experience of over 20 years in organizing international conferences, covering almost every field of life-science, Allied…

BySenior EditorMarch 4, 2020

Skyhawk Therapeutics Enters a ~$2B Deal with Merck KGaA to Identify RNA-Targeting Small Molecules for Neurological Disorders

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

8th International Conference on Neurology and Neuroscience 2020

Contact US

OUR INFORMATION

FOLLOW US